Arcturus Bioscience, Inc. Appoints Chief Executive Officer 
10/19/2005 5:12:56 PM

MOUNTAIN VIEW, Calif., March 7 /PRNewswire/ -- Arcturus Bioscience, Inc., announced today that Antonius Schuh, Ph.D., has been appointed Chief Executive Officer and will be elected a member of the company's Board of Directors. Dr. Schuh succeeds Thomas M. Baer, Ph.D., Founder and former Chief Executive Officer, who resigned at the end of the year after notifying the Arcturus Board of his intention to leave the company the previous summer. Dr. Baer has been appointed a Consulting Professor in the Applied Physics Department at Stanford University and continues to serve as a director of Arcturus.

Dr. Schuh joins Arcturus from Sequenom, Inc., where he served as Chief Executive Officer from May 2000 to February 2005. Prior positions at Sequenom include Managing Director of Sequenom GmbH, the company's initial operations in Germany, and Executive Vice President of Business Development. While Dr. Schuh served as CEO, Sequenom introduced the MassARRAY product line, developed numerous strategic collaborations and made a strategic transition that leveraged the company's technology and genetic content into the molecular medicine marketplace.

Dr. Schuh stated, "I am very excited to be leading an outstanding organization like Arcturus at a time when the company is ideally positioned for extensive growth into the clinical research and molecular diagnostic space. I am impressed by the exceptional quality and commitment of the current management team and by the accomplishments so far. Arcturus is internationally recognized as the leading supplier of laser capture microdissection systems for the isolation of cancer cells, as demonstrated by the outstanding success of the new Veritas(TM) system, which supports laser cutting and microdissection for very gentle isolation of single cells. A recently announced collaboration with Agendia BV of the Netherlands demonstrates Arcturus' leadership position in the promising field of molecular profiling of cancer. The company intends to contribute significantly to optimized clinical solutions for better classification of tumors, improved selection of therapeutic options and more reliable prognosis of clinical outcomes for cancer patients."

Separately, the Company announced that Richard D. Kniss, who has served as a member of the Arcturus Board since January 2002, will be appointed non-executive Chairman.

Mr. Kniss was Senior Vice President and General Manager of the Life Science and Chemical Group of Agilent Technologies prior to his retirement in 2001 after 34 years with Agilent and Hewlett Packard. Mr. Kniss stated, "We are very pleased to welcome Dr. Schuh to Arcturus. His background, experience and strategic vision will provide enormous value as the company expands into the clinical diagnostic space with its advanced development program of gene signatures for the molecular profiling of cancer."

About Arcturus Bioscience, Inc.:

Arcturus is the industry leader in Laser Capture Microdissection (LCM) and reagent systems for microgenomics, the molecular analysis of microscopic tissue samples, with systems installed in leading cancer centers and other research and clinical laboratories worldwide. These tools enable researchers to perform rapid cell-based analysis of disease progression utilizing the smallest and purest samples currently available. The company has developed this unique technology platform for genetic analysis of biopsy samples and has applied its platform to discover cell-specific gene signatures associated with human diseases such as cancer. Gene signatures for tumor identification and breast cancer prognosis are in late stage clinical development. Arcturus is a private company headquartered in Mountain View, California.

Arcturus Bioscience, Inc.

CONTACT: Robert A. Schueren of Arcturus Bioscience, +1-650-962-3020